X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (634) 634
index medicus (455) 455
male (441) 441
female (426) 426
transplantation (392) 392
hematology (385) 385
adult (334) 334
middle aged (302) 302
oncology (290) 290
bone-marrow-transplantation (280) 280
busulfan (273) 273
busulfan - administration & dosage (263) 263
adolescent (251) 251
immunology (245) 245
hematopoietic stem cells (211) 211
stem-cell transplantation (209) 209
hematopoietic stem cell transplantation (205) 205
pharmacokinetics (202) 202
child (201) 201
stem cells (193) 193
intravenous busulfan (181) 181
aged (175) 175
transplantation conditioning - methods (173) 173
children (171) 171
child, preschool (168) 168
treatment outcome (168) 168
infusions, intravenous (158) 158
transplantation, homologous (157) 157
busulfan - pharmacokinetics (151) 151
pharmacology & pharmacy (148) 148
cyclophosphamide (143) 143
infant (140) 140
daily intravenous busulfan (137) 137
retrospective studies (132) 132
hematopoietic stem cell transplantation - methods (123) 123
young adult (122) 122
analysis (111) 111
versus-host-disease (111) 111
chemotherapy (110) 110
stem cell transplantation (105) 105
health aspects (102) 102
fludarabine (101) 101
injections, intravenous (100) 100
hematopoietic stem cell transplantation - adverse effects (98) 98
transplantation conditioning (96) 96
hematology, oncology and palliative medicine (95) 95
total-body irradiation (95) 95
vidarabine - analogs & derivatives (92) 92
pediatrics (91) 91
busulfan - therapeutic use (87) 87
dosage and administration (84) 84
therapy (84) 84
care and treatment (83) 83
disease-free survival (83) 83
cancer (82) 82
leukemia (82) 82
toxicity (81) 81
busulfan - adverse effects (80) 80
dose-response relationship, drug (79) 79
acute myeloid-leukemia (76) 76
conditioning regimen (75) 75
survival analysis (74) 74
research (73) 73
bone marrow (70) 70
survival rate (69) 69
bone marrow transplantation (68) 68
cyclophosphamide - administration & dosage (68) 68
myeloablative agonists - administration & dosage (68) 68
oral busulfan (68) 68
hematologic neoplasms - therapy (67) 67
intravenous administration (67) 67
immunosuppressive agents - administration & dosage (66) 66
area under curve (65) 65
bone-marrow transplantation (65) 65
venoocclusive disease (65) 65
graft vs host disease - prevention & control (63) 63
mortality (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (62) 62
preparative regimen (62) 62
hepatic venoocclusive disease (60) 60
risk factors (60) 60
animals (59) 59
high-dose busulfan (59) 59
administration, oral (58) 58
medicine & public health (58) 58
article (57) 57
antineoplastic agents, alkylating - administration & dosage (56) 56
transplantation, autologous (56) 56
vidarabine - administration & dosage (56) 56
pediatric-patients (55) 55
drug administration schedule (53) 53
recurrence (53) 53
hematologic malignancies (52) 52
hemopoiesis (52) 52
transplants & implants (52) 52
blood (51) 51
disease (50) 50
prospective studies (50) 50
recipients (50) 50
follow-up studies (49) 49
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Gerstein Science - Missing (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Mt Sinai Hospital - Stacks (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (775) 775
Japanese (4) 4
French (3) 3
German (3) 3
Spanish (3) 3
Chinese (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2008, Volume 14, Issue 6, pp. 672 - 684
Abstract We postulated that fludarabine (Flu) instead of cyclophosphamide (Cy) combined with i.v. busulfan (Bu) as preconditioning for allogeneic hematopoietic... 
Hematology, Oncology and Palliative Medicine | AML | Cyclophosphamide | Fludarabine | i.v. Busulfan | Allogeneic stem cell transplantation | MDS | TOTAL-BODY IRRADIATION | CHRONIC MYELOGENOUS LEUKEMIA | BONE-MARROW-TRANSPLANTATION | RISK MYELODYSPLASTIC SYNDROME | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | allogeneic stem cell transplantation | DAILY INTRAVENOUS BUSULFAN | ACUTE LYMPHOBLASTIC-LEUKEMIA | fludarabine | cyclophosphamide | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | i.v. busulfan | Peripheral Blood Stem Cell Transplantation - adverse effects | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Busulfan - administration & dosage | Transplantation, Homologous | Antilymphocyte Serum - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Leukemia, Myeloid, Acute - surgery | Transplantation Conditioning - methods | Myelodysplastic Syndromes - surgery | Myelodysplastic Syndromes - drug therapy | Drug Administration Schedule | T-Lymphocytes | Treatment Outcome | Combined Modality Therapy | Vidarabine - analogs & derivatives | Peripheral Blood Stem Cell Transplantation - statistics & numerical data | Disease-Free Survival | Melphalan - administration & dosage | Adolescent | Bayes Theorem | Survival Analysis | Tissue Donors - statistics & numerical data | Myeloablative Agonists - administration & dosage | Vidarabine - administration & dosage | Infusions, Intravenous | Antimitotic agents | Chemotherapy | Influenza | Analysis | Leukemia | Alkylating agents | Transplantation | Antineoplastic agents | Hematopoietic stem cells | Cancer | Allogeneic Stem Cell Transplantation | IV Busulfan
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2019, Volume 59, Issue 5, pp. 638 - 645
This study aimed to predict the area under the curve (AUC) of the initial busulfan dose using a test dose with the sparse sampling scheme in adult patients who... 
busulfan | HCT | pharmacokinetics | test dose | transplantation | STRATEGY | FLUDARABINE | CHILDREN | SYSTEMIC EXPOSURE | PEDIATRIC-PATIENTS | PHARMACOLOGY & PHARMACY | ORAL BUSULFAN | STEM-CELL TRANSPLANTATION | ASSOCIATION | DAILY IV BUSULFAN | Root-mean-square errors | Intravenous administration | Mean square errors | Pharmacology | Busulfan | Conditioning | Sampling | Bayesian analysis | Patients | Hemopoiesis
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 09/2016, Volume 22, Issue 9, pp. 1588 - 1595
High-dose busulfan (Bu) is an integral component of commonly used preparative regimens for both allogeneic and autologous transplantation. There is significant... 
Lymphoma | Autologous stem cell transplantation | Busulfan | CONVENTIONAL CHEMOTHERAPY | BONE-MARROW-TRANSPLANTATION | RANDOMIZED-TRIAL | FOLLICULAR LYMPHOMA | IMMUNOLOGY | CONDITIONING REGIMEN | TRANSPLANTATION | HIGH-DOSE THERAPY | DAILY INTRAVENOUS BUSULFAN | NON-HODGKINS-LYMPHOMA | TERM-FOLLOW-UP | HEMATOLOGY | DAILY IV BUSULFAN | Humans | Middle Aged | Male | Transplantation, Autologous | Hematopoietic Stem Cell Transplantation - mortality | Busulfan - administration & dosage | Cyclophosphamide - therapeutic use | Lymphoma - mortality | Young Adult | Lymphoma - drug therapy | Lymphoma, Non-Hodgkin - complications | Hematopoietic Stem Cell Transplantation - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Retrospective Studies | Lymphoma, Non-Hodgkin - drug therapy | Liver Function Tests | Busulfan - pharmacokinetics | Busulfan - therapeutic use | Drug Administration Schedule | Etoposide - therapeutic use | Treatment Outcome | Hodgkin Disease - complications | Busulfan - toxicity | Lymphoma - complications | Aged | Lymphoma, Non-Hodgkin - mortality | Hematopoietic Stem Cell Transplantation - methods | Respiratory Function Tests | Cyclophosphamide | Patient outcomes | Analysis | Stem cells | Etoposide | Lymphomas | Transplantation | Carbon monoxide | Liver | Mortality | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 701 - 709
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 5/2012, Volume 51, Issue 5, pp. 331 - 345
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1525 - 1536
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 28, pp. 3549 - 3549
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 500 - 514
Journal Article